A Real-world Study for Patients With Multiple Pulmonary Ground-glass Nodules

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04192201

Enrollment

200

Registered

2019-12-10

Start date

2019-12-31

Completion date

2024-12-31

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Pulmonary Nodules

Keywords

Multiple Pulmonary Nodules, Lung Neoplasms

Brief summary

The purpose of this study is to actively monitor patients with multiple pulmonary Ground-glass Nodules (GGNs), in order to provide evidence for multiple GGNs treatment.

Detailed description

Multiple pulmonary GGNs are very commonly identified particularly as increasing numbers of CT scans are performed as part of routine lung cancer screening. At the same time, the ideal solution for these cases continues to be debated. This aim of this study is to learn more about the effects of multiple factors on outcome of multiple pulmonary GGNs, such as patients' clinical characteristics, CT features and different pathological types. Furthermore, the optimal timing of surgery and the effect of different surgical choices on the prognosis of patients with multiple GGNs will be investigated.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age greater than 18 years 2. Have two or more GGNs on CT imaging 3. Diameter of GGNs \> 5mm and ≤ 3cm 4. GGNs must be greater than half ground glass

Exclusion criteria

1. patients who have a history of lung cancer 2. patients who have undergone chemotherapy, radiotherapy or targeted therapy before surgery 3. pregnant women

Design outcomes

Primary

Measure	Time frame	Description
5-year overall survival [Time Frame: From date of the recruitment, assessed up to 60 months]	October 31, 2024	5-year overall survival

Secondary

Measure	Time frame	Description
5-year Progression-Free-Survival [Time Frame: From date of the recruitment, assessed up to 60 months]	October 31, 2024	5-year Progression-Free-Survival
Recurrence-free survival [Time Frame: From date of the recruitment, assessed up to 60 months]	October 31, 2024	Recurrence-free survival

Countries

China

Contacts

Primary ContactXiangning Fu, MD

fuxn2006@aliyun.com+8613607150390

Outcome results